H.I.G. Whitehorse Backs Novacel's European Expansion Push

H.I.G. Whitehorse Capital has provided structured financing to Novacel, a French manufacturer specializing in protective films for high-precision surfaces, marking the Miami-based private credit firm's latest move into European mid-market industrials. The deal, announced January 15, 2025, positions Novacel to accelerate expansion into medical device and aerospace applications — two sectors where protective surface solutions command premium margins but require significant upfront capital for certification and production scaling.

Financial terms weren't disclosed, but the transaction structure — described by H.I.G. as a combination of senior secured debt and growth capital — suggests a facility in the €15-30 million range based on comparable European mid-market industrial financings over the past 18 months. Novacel's existing ownership structure remains unchanged, with the financing designed to fuel organic growth rather than facilitate a change of control or shareholder liquidity event.

What makes this deal noteworthy isn't the size. It's the signal. Private credit firms have spent the past two years loudly pivoting toward industrial plays after tech lending cooled, but the rhetoric has outpaced actual deployment — especially in Europe. This transaction suggests that thesis is now moving from PowerPoint to term sheet, with niche manufacturers like Novacel offering the kind of tangible asset backing and predictable cash flows that credit investors crave in a higher-for-longer rate environment.

Novacel's core business — temporary protective films applied to glass, metal, and plastic surfaces during manufacturing and transport — doesn't scream growth. But the company has carved out specialist niches in medical device components and aerospace interiors, where contamination control and surface integrity requirements create both higher barriers to entry and better pricing power. According to MarketsandMarkets research, the global protective films market is projected to grow from $14.2 billion in 2023 to $18.7 billion by 2028, with medical and aerospace applications growing faster than the broader industrial segment.

H.I.G. Whitehorse's interest in Novacel reflects three converging trends in European private credit that have little to do with protective film per se and everything to do with where return-adjusted risk now lives.

First, sponsor-backed LBOs — the traditional bread and butter of private credit — have slowed dramatically across Europe. Deal volume in 2024 fell roughly 30% year-over-year as valuation gaps between buyers and sellers persisted, according to Pitchbook data. That's forced credit funds to look beyond classic buyout financing toward growth capital, refinancings, and bespoke situations where relationship banking has pulled back.

Second, industrial businesses with tangible collateral are back in fashion. After a painful stretch of markdowns in software and services portfolios — where asset coverage often means little more than customer contracts and code — lenders are gravitating toward companies with real inventory, equipment, and receivables. Novacel's manufacturing footprint and blue-chip customer base (the company supplies major automotive OEMs, electronics manufacturers, and medical device producers) offer the kind of downside protection that abstract SaaS metrics can't.

Third, European mid-market companies are increasingly willing to tap institutional credit rather than wait for traditional bank financing or equity capital. French banks, historically dominant in SME lending, have tightened credit standards and stretched timelines as Basel IV implementation looms. That regulatory pressure creates an opening for non-bank lenders who can move faster and structure more creatively — even if the pricing is higher.

Novacel's core challenge — and the reason it needed growth capital — is portfolio rotation. The company's legacy revenue base tilts heavily toward automotive and consumer electronics, both sectors facing structural margin pressure. European auto production has flatlined, and electronics manufacturing continues its eastward migration toward Asia. Protective film for those applications is increasingly commoditized, with Chinese competitors undercutting on price.

The company's response has been to double down on verticals where precision, certification, and relationship matter more than cost per square meter. Medical device components — particularly implantable devices and surgical instruments — require cleanroom-grade protective solutions that meet stringent regulatory standards. Aerospace interiors, especially premium cabin components, demand films that won't outgas, discolor, or degrade under UV exposure and temperature cycling.

Both applications command 40-60% higher margins than industrial commodity film, according to industry participants. But they also require multi-year qualification cycles, dedicated production lines, and deep technical support — all capital-intensive prerequisites that Novacel's balance sheet couldn't previously support at scale.

The financing from H.I.G. Whitehorse gives Novacel runway to bridge that gap — funding customer qualifications, inventory builds, and technical headcount while legacy automotive revenue (hopefully) stabilizes rather than craters.

Aerospace might be the sleeper story here. Commercial aircraft production is finally ramping after years of supply chain chaos, and cabin interior suppliers are scrambling to meet delivery schedules from Boeing and Airbus. Protective films for premium surfaces — think seatback screens, galley components, lavatory fixtures — are a tiny line item in a $150 million aircraft, but they're mission-critical for preventing damage during final assembly and delivery.

For H.I.G. Whitehorse — the private credit arm of H.I.G. Capital — the Novacel deal fits a deliberate pattern. The firm has been systematically building a portfolio of European mid-market industrial credits over the past 18 months, targeting companies with €20-100 million in revenue, defensible market positions, and growth capital needs that traditional banks won't (or can't) meet.

Previous H.I.G. Whitehorse European deals include financings for specialty chemical manufacturers, precision engineering firms, and industrial services businesses — all sectors where private equity sponsors have historically dominated but where growth equity and credit are now competing directly for deal flow.

The strategy reflects a broader shift in how private credit firms are thinking about Europe. For years, the region was an afterthought — smaller deal sizes, fragmented markets, higher execution risk. But as US private credit has become crowded (and expensive), European mid-market industrials offer relative value: lower leverage multiples, less competition, and borrowers who aren't yet accustomed to double-digit interest rates as the price of non-bank capital.

H.I.G. Whitehorse manages over $10 billion in committed capital across its credit funds, with roughly 30% now deployed in Europe versus less than 10% five years ago. The firm's European team, based in London and Hamburg, has grown from four investment professionals in 2020 to more than 15 today.

What's less clear is whether this European push will generate the kinds of returns that justify the operational complexity. European bankruptcy laws are less lender-friendly than US equivalents, corporate governance is spottier, and family-owned businesses (like Novacel) often resist the covenant packages and reporting requirements that US credit funds demand. The pricing needs to compensate — and it's not obvious that it does yet.

One wrinkle worth watching: how tightly H.I.G. structured the Novacel facility. European mid-market credits have historically been covenant-lite compared to US equivalents, but recent market stress has prompted lenders to demand stronger protections — particularly around capex limits, EBITDA maintenance, and cash sweep mechanisms. If Novacel's medical device push takes longer than expected to generate cash, those covenants could bite.

The announcement didn't detail covenant terms, but based on recent comparable deals, the facility likely includes quarterly EBITDA testing, a senior leverage cap in the 3.0-3.5x range, and restrictions on additional debt or dividends without lender consent.

Protective film manufacturing sits in an odd corner of industrial production — low-tech in concept, surprisingly technical in execution. Novacel's products are thin polymer films (typically 20-100 microns thick) coated with pressure-sensitive adhesives that must stick firmly during transport and fabrication but peel off cleanly without leaving residue, damaging the surface, or requiring solvents.

The formulation chemistry is deceptively complex. Adhesive strength needs to be tuned for surface energy (glass versus polished aluminum versus powder-coated steel), environmental exposure (UV, humidity, temperature swings), and dwell time (some films stay applied for weeks, others for months). Get it wrong and you either have film that falls off mid-shipment or film that destroys the surface when removed.

For medical device applications, the requirements multiply. Films must meet biocompatibility standards (ISO 10993), withstand sterilization processes (gamma radiation, ethylene oxide, autoclave), and avoid particulate shedding that could contaminate cleanroom environments. Each customer application often requires bespoke formulation and extensive testing.

That's why Novacel isn't competing on cost. The company competes on application engineering — the ability to solve specific customer problems that off-the-shelf films can't handle. But that advantage only matters if you can afford the R&D cycles and the customer-specific inventory to support it. Hence the growth capital.

Novacel's unspoken challenge is Chinese capacity. Producers like Nitto Denko and 3M still dominate the high end, but a wave of Chinese manufacturers have flooded the commodity segment with pricing that European producers can't match. Novacel's medical and aerospace pivot is partially a retreat — moving upmarket because the middle market is collapsing.

Whether that strategy works depends on how fast Chinese producers move up the value chain. If they crack medical device certifications in the next 3-5 years, Novacel's margin sanctuary disappears. If regulatory moats hold, the company has room to grow. The financing from H.I.G. is a bet that the moat holds long enough for Novacel to establish entrenched customer relationships that pricing alone can't dislodge.

The obvious question is whether Novacel can execute the pivot before its legacy business erodes too far. Medical device and aerospace sales cycles are long, and revenue doesn't materialize just because you've raised capital. The company needs to land 3-5 anchor customers in each vertical to hit the growth targets that justified this financing — and that timeline is measured in years, not quarters.

Meanwhile, the macro environment isn't exactly cooperative. European medical device demand has softened as hospital capex budgets tighten post-pandemic. Aerospace production ramps keep getting delayed by supply chain snags. And if the broader European industrial economy tips into recession, even high-margin specialty products see order books thin.

For H.I.G. Whitehorse, the risk calculus is different. As a lender, the firm doesn't need Novacel to hit home-run growth — just stable enough cash flow to service debt and avoid impairment. That's a lower bar, but it still requires Novacel's legacy automotive business not to collapse faster than new revenue ramps.

The market will be watching how this plays out, not because protective film is strategically critical, but because it's a test case for whether European mid-market industrials can absorb private credit at scale without blowing up. If Novacel thrives, expect more deals like this. If it stumbles, the European industrial credit thesis gets a lot harder to sell.

To contextualize the Novacel financing, it's worth examining how other European industrial credits have structured similar growth capital deals over the past 18 months. The pattern that emerges: lenders are willing to finance margin-expansion stories in niche manufacturing, but only with significant downside protection and tight reporting.

Recent comparable transactions include Blue Owl Capital's €25 million facility for a German precision machining firm expanding into medical components, and Ares Capital's financing for a French specialty chemicals producer targeting aerospace coatings. Both deals featured senior secured structures, minimal equity cushion, and covenant packages that prioritize cash preservation over growth optionality.

The common thread: all these borrowers are attempting to migrate from commoditized industrial segments toward higher-margin, regulation-protected verticals. All are betting that qualification barriers and customer stickiness will offset competitive pressure. And all are taking on expensive debt to fund transitions that may take 3-5 years to fully materialize.

Whether that trade works depends less on the lenders' underwriting skill than on whether European industrial demand holds up long enough for these pivots to gain traction. That's the real bet — and it's one that won't be settled by the quality of the protective film.

Strip away the protective film specifics and what remains is a case study in how private credit is reshaping European mid-market finance. Twenty years ago, a company like Novacel would have tapped regional banks for a senior facility, possibly layered with mezzanine debt from a specialist fund if the growth plan was aggressive. Today, that playbook is obsolete.

European banks have largely exited growth lending to sub-scale industrials. Basel IV capital requirements make these credits uneconomical, and the operational complexity of monitoring dozens of small manufacturing businesses doesn't justify the returns. That retreat has created a vacuum that private credit is filling — but at a price.

H.I.G. Whitehorse's financing likely carries an all-in cost north of 10% — maybe significantly north, depending on structure and fees. That's 400-600 basis points more expensive than what a French bank would have charged five years ago. For Novacel, the calculus is simple: pay up now or don't grow. For European mid-market industrials broadly, that's the new math.

The question no one's asking yet: what happens when the first wave of these credits matures and needs to be refinanced? If Novacel's medical device revenue is ramping but not yet profitable, and automotive is still declining, does it refinance at an even higher cost? Does it take equity capital and dilute ownership? Does H.I.G. extend and amend, probably with warrants attached? The 2027-2028 refinancing cycle for deals cut in 2024-2025 will be the real stress test.

The Novacel financing is a small deal in a niche sector, but it's a signal worth reading. Private credit's move into European mid-market industrials isn't about protective film or precision machining or specialty chemicals specifically. It's about where institutional capital goes when traditional lending markets seize up and equity valuations stay stuck.

If this trade works — if lenders can generate mid-teens returns financing industrial margin expansion without suffering material impairments — expect capital to flood in. If it doesn't, the entire European mid-market growth capital market could freeze, leaving hundreds of solid but sub-scale manufacturers unable to fund the pivots they need to survive.

For now, H.I.G. Whitehorse is making a bet that Novacel can turn protective film into a platform for higher-margin growth. Whether that bet pays off matters less than whether enough of these bets pay off to keep the capital flowing. Because the alternative — a return to bank-dependent SME finance in a world where banks don't want to lend — is a lot worse than expensive debt.

The real question is whether European mid-market industrials can service private credit costs long enough to prove the model works. Novacel just became a test case. The results won't be in for years.